486 / 1498
0
0.2
0.4
0.6
0.8
1
0
12
24
36
48
60
Time after RIC-allo, months
CI NRM
Age >45 yrs, RR 2.4 (1.1 – 5.0),
P
= .05
Performance status ≥2, RR 3.9 (1.8 – 7.3),
P
= .05
Refractory disease, RR 2.6 (1.5 – 4.5),
P
= .01
15% at 1 yr
17% at 2 yrs
19% at 3 yrs
8% at 100 days
Sureda A, et al. Blood. 2009;114: A 658
RIC-Allo Trial in Relapsed
or Refractory HL (Non-relapse Mortality)
RIC-allo - reduced-intensity conditioning allogenic stem cell transplantation; HL –
Hodgkin lymphoma; NRM – non-relapse mortality